Abstract Number: 0019 • ACR Convergence 2025
Single cell characterization of the circulating immune system in Sjögren’s Syndrome
Background/Purpose: Sjögren’s syndrome (SS) is a chronic autoimmune disease characterized by the infiltration of circulating immune cells into the salivary and lacrimal glands. The properties…Abstract Number: 2297 • ACR Convergence 2025
Clinically Relevant Anti-Vaccine and Virus Antibodies in Patients with Sjogren’s Disease Treated with Nipocalimab: Post-Hoc Analysis of the DAHLIAS Study
Background/Purpose: Nipocalimab is a fully human, high affinity, aglycosylated, effectorless IgG1 monoclonal antibody designed to selectively block neonatal fragment crystallizable receptor (FcRn), thereby lowering serum…Abstract Number: 1939 • ACR Convergence 2025
Salivary Gland Ultrasounds Can Be Read by General Radiologists: A Review Of 4 Years of Reports from an Urban Academic Radiology Department
Background/Purpose: Salivary gland ultrasound (SGUS) has the potential to inform diagnosis and progression of Sjogren’s disease, a systemic autoimmune disease which results in progressive inflammation…Abstract Number: 1399 • ACR Convergence 2025
Significance of Antiphospholipid Antibodies in Patients with Sjogren’s Disease
Background/Purpose: A few reports have evaluated the frequency of antiphospholipid antibodies (aPL) in Sjogren’s disease (SjD) and their association with SjD or Antiphospholipid Antibody Syndrome…Abstract Number: 1382 • ACR Convergence 2025
Interstitial lung disease in primary sjögren syndrome: pathochrony, seronegative cases, and Risk of progressive pulmonary fibrosis
Background/Purpose: Sjögren’s disease (SjD) is a chronic autoimmune disorder primarily targeting exocrine glands. A significant extraglandular manifestation is interstitial lung disease (ILD), which contributes to…Abstract Number: 0518 • ACR Convergence 2025
Deregulation of PSGL-1, HLA-DR and IFNα expression in peripheral innate immune cells of primary Sjögren Syndrome patients
Background/Purpose: Primary Sjögren's Syndrome (pSS) is an autoimmune disease characterized by lymphocytic infiltration of exocrine glands and systemic manifestations including cutaneous and renal involvement. Phagocytes--monocytes,…Abstract Number: 2298 • ACR Convergence 2025
When Imaging and Biopsy Disagree: Diagnostic Value of Doppler Ultrasound and Histologic Features beyond the Focus Score
Background/Purpose: Salivary gland ultrasound (SGUS) and minor salivary gland biopsy (MSGB) are widely used in the diagnosis of primary Sjögren’s syndrome (pSS). However, discordance between…Abstract Number: 1881 • ACR Convergence 2025
Silent Impact: Two Decades of Sjögren’s Syndrome Mortality in the United States
Background/Purpose: Sjögren’s syndrome is a chronic autoimmune disease characterized by lymphocytic infiltration of exocrine glands with potential systemic involvement. Despite its known complications, population-level mortality…Abstract Number: 1398 • ACR Convergence 2025
Reproductive Challenges and Cardiovascular Risks in Sjögren’s Syndrome and Systemic Sclerosis: A Meta-Analysis of Fertility, Pregnancy Outcomes, and Maternal Cardiac Health
Background/Purpose: Autoimmune rheumatic diseases such as Sjögren’s Syndrome (SS) and Systemic Sclerosis (SSc) can significantly impact reproductive health and increase maternal cardiovascular risk. These conditions…Abstract Number: 1381 • ACR Convergence 2025
Self-Reported and Actigraphic Sleep and Circadian Rhythm Disruptions in Patients with Sjögren’s Disease: Associations with Disease Activity and Patient-Reported Outcomes
Background/Purpose: Patients with Sjögren’s Disease (SjD) frequently report debilitating symptoms such as pain, fatigue, and dryness, significantly impacting health-related quality of life. Although sleep disturbances…Abstract Number: 0517 • ACR Convergence 2025
Gut Microbiota Dysbiosis and Clinical Predictors of Fatigue in Primary Sjögren’s Syndrome: A Multi-Omics Study
Background/Purpose: Fatigue affects 70% of primary Sjögren's syndrome (pSS) patients, but its mechanisms remain unclear. We investigated clinical predictors and gut microbiota associations in pSS-related…Abstract Number: PP08 • ACR Convergence 2025
Living Well Despite the Challenges of Sjögren’s Disease and Systemic Lupus Erythematous: My Perspective as a Health Care Provider and Patient
Background/Purpose: Typically, the diagnosis of any autoimmune condition can be challenging and take years. In my case, my diagnosis of Sjögren's disesase (SjD) was established…Abstract Number: 2296 • ACR Convergence 2025
Evaluation of the Dual Mode of Action of Ianalumab (VAY736) in the Circulation and Salivary Gland Tissue of Patients With Sjögren’s Disease: Results From a Phase 2 Mechanistic Study
Background/Purpose: Ianalumab, a glycoengineered, fully human, IgG1 mAb directed against B cell-activating factor (BAFF)-receptor (BAFF-R), targets B cells and their functions via a dual mechanism…Abstract Number: 1684 • ACR Convergence 2025
Integration of Multiple Spatial Transcriptomics Reveals Novel Insights into Sjogren Disease Salivary Gland Fibroblast by Peripheral Serostatus
Background/Purpose: Anti-SSA antibody positive (SSA+ [Ro52 or Ro60]) and negative (SSA-) Sjögren disease (SjD) have differing clinical phenotypes and prognostic features; however, the pathogenesis driving…Abstract Number: 1397 • ACR Convergence 2025
Cardiovascular And Cerebrovascular Risk In Sjögren’s Disease: Results From A Prospective Multicenter Cohort.
Background/Purpose: To evaluate the incidence of cardiovascular and cerebrovascular events (CVEs) in patients with Sjögren’s Disease (SjD), focusing on major adverse cardiovascular events (MACE), defined…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 24
- Next Page »